Egle A - Search Results

1

Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies.

Magnes T, Wagner S, Thorner AR, Neureiter D, Klieser E, Rinnerthaler G, Weiss L, Huemer F, Schlick K, Zaborsky N, Steiner M, Greil R, Egle A, Melchardt T. Magnes T, et al. Among authors: egle a. Cancers (Basel). 2021 Feb 6;13(4):650. doi: 10.3390/cancers13040650. Cancers (Basel). 2021. PMID: 33561953 Free PMC article.

2

Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.

Villunger A, Egle A, Kos M, Hittmair A, Maly K, Greil R. Villunger A, et al. Among authors: egle a. Int J Cancer. 1996 Feb 8;65(4):498-505. doi: 10.1002/(SICI)1097-0215(19960208)65:4<498::AID-IJC18>3.0.CO;2-6. Int J Cancer. 1996. PMID: 8621234

3

2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).

Gruber J, Geisen F, Sgonc R, Egle A, Villunger A, Boeck G, Konwalinka G, Greil R. Gruber J, et al. Among authors: egle a. Stem Cells. 1996 May;14(3):351-62. doi: 10.1002/stem.140351. Stem Cells. 1996. PMID: 8724701

4

Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.

Egle A, Villunger A, Kos M, Böck G, Gruber J, Auer B, Greil R. Egle A, et al. Eur J Immunol. 1996 Dec;26(12):3119-26. doi: 10.1002/eji.1830261244. Eur J Immunol. 1996. PMID: 8977313

5

Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.

Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R. Egle A, et al. Br J Haematol. 1997 May;97(2):418-28. doi: 10.1046/j.1365-2141.1997.382680.x. Br J Haematol. 1997. PMID: 9163609 Free article.

6

Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.

Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Villunger A, et al. Among authors: egle a. Cancer Res. 1997 Aug 15;57(16):3331-4. Cancer Res. 1997. PMID: 9269989

7

On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.

Greil R, Egle A, Villunger A. Greil R, et al. Among authors: egle a. Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.

8

Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.

Tinhofer I, Marschitz I, Henn T, Egle A, Greil R. Tinhofer I, et al. Among authors: egle a. Blood. 2000 Jan 15;95(2):610-8. Blood. 2000. PMID: 10627470 Free article.

9

Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.

Marschitz I, Tinhofer I, Hittmair A, Egle A, Kos M, Greil R. Marschitz I, et al. Among authors: egle a. Am J Clin Pathol. 2000 Feb;113(2):219-29. doi: 10.1309/491W-L1TN-UFQX-T61B. Am J Clin Pathol. 2000. PMID: 10664624

10

Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia.

Tinhofer I, Rubenzer G, Holler C, Hofstaetter E, Stoecher M, Egle A, Steurer M, Greil R. Tinhofer I, et al. Among authors: egle a. Blood. 2006 Nov 1;108(9):2950-6. doi: 10.1182/blood-2006-03-010553. Epub 2006 Jul 6. Blood. 2006. PMID: 16825496 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters